Get the Stockscreener App
5.52
5.32%
-0.31
Taysha Gene Therapies Inc stock is traded at $5.52, with a volume of 1.81M.
It is down -5.32% in the last 24 hours and down -20.46% over the past month.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
See More
Previous Close:
$5.83
Open:
$5.89
24h Volume:
1.81M
Relative Volume:
0.62
Market Cap:
$1.59B
Revenue:
$7.47M
Net Income/Loss:
$-129.88M
P/E Ratio:
-13.93
EPS:
-0.3962
Net Cash Flow:
$-115.33M
1W Performance:
-7.38%
1M Performance:
-20.46%
6M Performance:
+18.45%
1Y Performance:
+113.13%
1-Day Range:
$5.46
$5.95
1-Week Range:
$5.46
$6.05
52-Week Range:
$2.525
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.52 | 1.59B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
TSHA Maintains Buy Rating -- Price Target Raised to $13.00 by Go - GuruFocus
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In - Yahoo Finance
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing - Moomoo
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run - The Motley Fool
Taysha Gene Therapies president sells $1.25m in stock By Investing.com - Investing.com India
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G - GuruFocus
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA) - GuruFocus
Taysha Gene Therapies president sells $1.25m in stock - Investing.com
Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
Form 144 Taysha Gene Therapies For: 10 July By Investing.com - Investing.com Nigeria
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative? - simplywall.st
TSHA Q1 2026 Earnings: EPS Miss of -$0.12 vs. -$0.0996 Estimate; Stock Declines MarginallyManagement Guidance Update - dars.gov.et
If You Invested $1,000 in Taysha Gene Therapies, Inc. (TSHA) - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com India
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
TSHA Reiterated by Citizens -- Price Target Maintained at $11.00 - GuruFocus
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue - Sahm
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15 - Moomoo
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Needham -- Price Target Holds at $12.00 - GuruFocus
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Baird -- Price Target Raised to $15.00 - GuruFocus
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies shows 100% response in Re... - Pluang
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
Enterprise value to EBIT forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside - TradingView
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell 3000E Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell Microcap Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Taysha Gene Therapies launches $200M public offering; shares down - MSN
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - The Manila Times
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M - MSN
Form 424B5 Taysha Gene Therapies Inc For: 25 June By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference - Investing.com
Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants - Stock Titan
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting - Traders Union
Taysha Gene Therapies (TSHA) priced 32.5M-share offering; $187M net proceeds - Stock Titan
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):